Scarica l'app Stockscreener
76.06
1.35%
1.1103
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARWR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$74.95
Aprire:
$75.07
Volume 24 ore:
449.48K
Relative Volume:
0.22
Capitalizzazione di mercato:
$10.71B
Reddito:
$622.01M
Utile/perdita netta:
$-271.86M
Rapporto P/E:
-35.40
EPS:
-2.1484
Flusso di cassa netto:
$-45.87M
1 W Prestazione:
+3.80%
1M Prestazione:
+2.78%
6M Prestazione:
+31.63%
1 anno Prestazione:
+402.07%
Intervallo 1D:
$74.07
$76.55
Intervallo di 1 settimana:
$73.75
$77.49
Portata 52W:
$14.30
$82.26
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Nome
Arrowhead Pharmaceuticals Inc
Settore
Industria
Telefono
626-696-4702
Indirizzo
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
76.05 | 10.56B | 622.01M | -271.86M | -45.87M | -2.1484 |
VRTX
Vertex Pharmaceuticals Inc
|
437.62 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.93 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.39 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.04 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.69 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Neutral |
| 2023-12-04 | Iniziato | BofA Securities | Buy |
| 2023-09-19 | Iniziato | Citigroup | Neutral |
| 2023-07-21 | Iniziato | TD Cowen | Outperform |
| 2023-05-12 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-12 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Ripresa | Goldman | Buy |
| 2021-08-06 | Reiterato | Chardan Capital Markets | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-19 | Iniziato | Citigroup | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-05-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Iniziato | Goldman | Neutral |
| 2020-01-21 | Iniziato | SVB Leerink | Underperform |
| 2019-12-13 | Iniziato | Oppenheimer | Perform |
| 2019-11-29 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-27 | Reiterato | B. Riley FBR | Buy |
| 2019-11-25 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Reiterato | Chardan Capital Markets | Buy |
| 2019-10-03 | Iniziato | Robert W. Baird | Outperform |
| 2018-09-07 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-08-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Arrowhead Pharmaceuticals Inc Borsa (ARWR) Ultime notizie
Arrowhead presents plozasiran data on renal, hepatic impairment By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress - Arrowhead Pharmaceuticals, Inc.
Bernstein Lifts PT on Arrowhead Pharmaceuticals (ARWR) Following Biotech’s Solid Start to 2026 - Insider Monkey
Avoiding Lag: Real-Time Signals in (ARWR) Movement - Stock Traders Daily
ARROWHEAD PHARMACEUTICALS IN (ARWR) Technical Analysis - ChartMill
Arrowhead’s ARO-CFB Kidney Trial Completion: What Investors Should Watch Next - TipRanks
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum - Yahoo Finance
Arrowhead Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Director Daniel Apel to offer 100,000 ARWR common shares (NASDAQ: ARWR) - Stock Titan
Insider Hongbo Lu notifies sale of 2,970 ARWR shares (NASDAQ: ARWR) - Stock Titan
James Hamilton to sell 10,000 shares (ARWR) after prior 10,000-share sale - Stock Titan
Arrowhead Pharmaceuticals eyes $4B Redemplo opportunity as RNAi pipeline readouts near - MSN
Arrowhead Licenses ARO PNPLA3 To Madrigal To Expand MASH Options - Sahm
Q4 2025 Arrowhead Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
What is Zacks Research's Estimate for ARWR FY2026 Earnings? - MarketBeat
Baader Bank Aktiengesellschaft Purchases Shares of 14,194 Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat
Insider Sell: Hongbo Lu Sells Shares of Arrowhead Pharmaceuticals Inc (ARWR) - GuruFocus
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 through May-14-2026 - marketscreener.com
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 2,970 Shares of Stock - MarketBeat
Arrowhead director Lu Hongbo sells $228,333 of common stock - Investing.com
Arrowhead (NASDAQ: ARWR) director sells 2,970 shares under Rule 10b5-1 plan - Stock Titan
Arrowhead Pharmaceuticals, Inc.Common Stock (NQ: ARWR - FinancialContent
What is HC Wainwright's Forecast for ARWR Q3 Earnings? - MarketBeat
Arrowhead Pharmaceuticals stock hits 52-week high at $80.5 By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near - MarketBeat
ARWR Maintained by Bernstein -- Price Target Raised to $46.00 - GuruFocus
Sanford C. Bernstein Boosts Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $46.00 - MarketBeat
Arrowhead Pharmaceuticals stock hits 52-week high at $80.5 - Investing.com
HC Wainwright Issues Optimistic Outlook for ARWR Earnings - MarketBeat
ARWR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After Its Recent Share Price Momentum - Yahoo Finance
[144] ARROWHEAD PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Arrowhead Pharmaceuticals: A True Inflection Point Has Arrived (NASDAQ:ARWR) - Seeking Alpha
Goldman Sachs Maintains Arrowhead Pharmaceuticals (ARWR) Neutral Recommendation - MSN
Arrowhead Pharmaceuticals Jumps 7.9% After RBC Capital Maintains Outperform - AlphaStreet
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year High on Analyst Upgrade - MarketBeat
Discipline and Rules-Based Execution in ARWR Response - Stock Traders Daily
Has Arrowhead Pharmaceuticals (ARWR) Run Too Far After Its 488% One Year Surge - Sahm
Arrowhead Pharmaceuticals (ARWR) Q1 Profit Supports Bullish Narrative Despite High 54x P/E - Sahm
ViaSat, Arrowhead Pharmaceuticals, and SiTime Lead Stocks with High Returns - Markets Mojo
Arrowhead anticipates SHASTA-3/4 topline in Q3 while planning an SHTG sNDA before end of 2026 - MSN
Arrowhead Pharmaceuticals’ Earnings Call: Launch, Losses, Bets - TipRanks
ARWR Maintained by RBC Capital -- Price Target Raised to $87.00 - GuruFocus
Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - MSN
Piper Sandler Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $110 - Moomoo
RBC Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $87 - Moomoo
RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $87 From $80, Maintains Outperform Speculative Risk Rating - marketscreener.com
Chardan Capital Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $90 - Moomoo
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results - BioSpace
Arrowhead Pharma earnings up next: First Redemplo sales in focus - Investing.com
Arrowhead Pharmaceuticals (ARWR) Reports Strong Progress and Fut - GuruFocus
Arrowhead Pharmaceuticals Inc Azioni (ARWR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):